Clinical trials: Hematological Neoplasm
Castrate Resistant Prostate Cancer, NUT Carcinoma
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
- Conditions
- Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
- Trial name
- NCT05488548
- Testing
- EP31670
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- Epigenetix, Inc.
Advanced Solid Tumors or Hematologic Malignancies
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
APG-1387 is a potent, bivalent small-molecule Inhibitor of Apoptosis Protein (IAP) antagonist. APG-1387 has shown strong dose- and schedule-dependent antitumor activities in multiple human cancer xenograft models, APG-1387 also…
- Trial name
- NCT03386526
- Testing
- APG-1387 for Injection
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm
Remote Monitoring in Cancer Care: A Platform Study
This study investigates a device that closely monitors vital signs, as well as a smartphone application (app) that allows patients to respond to different questions and tests that will monitor for new symptoms.
- Conditions
- Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lung Carcinoma, Malignant Digestive System Neoplasm
- Trial name
- NCT05018208
- Testing
- Computer-Assisted Intervention, Patient Monitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
This phase II MATCH treatment trial investigates the good and bad effects of binimetinib in patients whose cancer has a genetic change called NRAS mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439344
- Testing
- Binimetinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy.
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma
- Trial name
- NCT04205409
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Hematological Malignancies, CMV Infection
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
Viral infections remain an important cause of morbidity and mortality after allogeneic stem cell transplantation (SCT), especially after myelo-ablative conditioning and if the donor is antigen-mismatched or haplo-identical..
- Trial name
- NCT03067155
- Testing
- CMV-specific T cells, Standard anti-viral therapy
- Where
- 8 sites in Belgium
- Volunteers
- 1 people
- Sponsor
- University Hospital, Ghent
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Hematologic Neoplasms
Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy is a promising new treatment that re-programs patient immune cells to target and destroy cancer cells.
- Trial name
- NCT04275154
- Sponsor
- University of Nebraska
Hematologic Malignancies
Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation
1. The purpose of this study is to determine the efficacy of ramosetron for the prevention of emesis and the control of nausea and vomiting despite of the prophylactic antiemetic treatment during hematopoietic stem cell…
- Trial name
- NCT01788605
- Testing
- ramosetron
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- The Catholic University of Korea
Hematologic Malignancy
Mindfulness and CBT for Sleep
Patients with hematologic cancer frequently report significant difficulties with sleep in the months after discharge from inpatient chemotherapy.
- Trial name
- NCT04736056
- Testing
- Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Polycythemia Vera
Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
The primary objective of this study is to determine the overall response rate to erlotinib in patients with polycythemia vera (PV).
- Trial name
- OSI-TAR-766 (NCT01038856)
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Oklahoma
Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as…
- Conditions
- Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes
- Trial name
- NCT04891757
- Testing
- FHD-286, Low Dose Cytarabine, Decitabine
- Where
- 5 sites in United States
- Volunteers
- 144 people
- Sponsor
- Foghorn Therapeutics Inc.
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Effective treatment options for relapsed/refractory acute myeloid leukemia (AML) and T-cell non-Hodgkin lymphoma (T-NHL) represent a significant unmet medical need.
- Conditions
- T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma
- Trial name
- NCT05377827
- Testing
- WU-CART-007
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Febrile Neutropenia, Hematological Malignancy
Early Antibiotic Discontinuation in FUO
Febrile neutropenia requires prompt initiation of broad-spectrum antibiotics, which can be responsible for side-effects and selection of resistance.
- Trial name
- ANTIBIOSTOP (NCT02906254)
- Testing
- ECIL-4 guidelines group, Short-course antibiotic therapy
- Where
- France
- Volunteers
- 123 people
- Sponsor
- University Hospital, Brest
Leukemia, Lymphoma
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00521430
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
This study will evaluate the efficacy of the combination entospletinib and idelalisib in participants with relapsed or refractory hematologic malignancies.
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma
- Trial name
- NCT01796470
- Testing
- Entospletinib, Idelalisib
- Where
- 13 sites in United States
- Volunteers
- 66 people
- Sponsor
- Gilead Sciences
Hematological Malignancies
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot…
- Trial name
- NCT00504803
- Testing
- Mesenchymal stem cell infusion
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Liege
Bone Marrow Transplant Complications
Assesment of Upper Egypt Experience in Autologous Bone Marrow Transplantation of Patients With Hematological Malignancies: A Cohor Study
Autologous hematopoietic stem cell transplantation (ASCT) is an important treatment for eligible patients with hematological malignancies, particularly multiple myeloma and relapsed lymphoma.
- Trial name
- NCT07823946
- Volunteers
- 123 people
- Sponsor
- Assiut University
Graft Versus Host Disease, Leukemia
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00005988
- Testing
- cyclophosphamide, cyclosporine, leucovorin calcium
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
High Risk Hematological Malignancy, Cord Blood Transplant
US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
Cord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality.
- Trial name
- NCT04103879
- Testing
- ECT-001-CB (UM171-Expanded Cord Blood Transplant)
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 30 people
- Sponsor
- ExCellThera inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.